| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Date of Report (Date of earliest event reported): November 16, 2026 |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures |
| 07 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Xtant Medical Holdings, Inc. (the “Company”) held an Annual Meeting of Stockholders (the “Annual Meeting”) on August 7, 2026. As of the close of business on June 9, 2026, the record date for the Annual Meeting, there were 140,262,960 sha... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Raises full-year 2026 revenue guidance to a range of $101-$105 million |
| 13 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon’s HEMOBLAST® Bellows Product |
| 31 Mar 2026 |
8-K: Results of Operations and Financial Condition
Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year |
| 02 Mar 2026 |
8-K: Other Events
As previously announced, on December 1, 2025, Xtant Medical Holdings, Inc. (the “Company”) sold certain assets relating to its Coflex and CoFix products and all of the outstanding capital stock of its wholly owned subsidiary engaged in t... |
| 16 Jan 2026 |
8-K: Other Events
As previously announced, on December 1, 2025, Xtant Medical Holdings, Inc. (the “Company”) and Surgalign SPV, Inc., a wholly owned subsidiary of the Company (together with the Company, the “Seller”), completed the sale of certain assets ... |
| 03 Dec 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Triggering Events That Accelerate a Financial Obligation +1 more
The following unaudited pro forma condensed consolidated financial information was derived from the historical consolidated financial statements of Xtant Medical Holdings, Inc. (the “Company”) as described in more detail below and is bei... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow |
| 10 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
XTANT MEDICAL HOLDINGS, inc. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow |
| 08 Aug 2025 |
8-K: Other Events
On August 8, 2025, the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”) established November 7, 2025 as the date of the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). The exact ... |
| 04 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 08 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
This Equity Purchase Agreement (this “Agreement”) dated July 7, 2025, by and between XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (the “Seller”), PARADIGM SPINE GMBH, a German Gesellschaft mit beschränkter Haftung (the “Company”)... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
Delivers Positive Net Income and $1.3 Million in Operating Cash Flow |
| 16 Apr 2025 |
8-K: Termination of a Material Definitive Agreement; Results of Operations and Financial Condition +3 more
Healthcare Focused Long-term Investors Support Strategic Vision |
| 11 Apr 2025 |
8-K: Entry into a Material Definitive Agreement
This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 10, 2025, by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto... |
| 06 Mar 2025 |
8-K: Results of Operations and Financial Condition
Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition
Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million |
Loading...